## Protocol Section
### Identification Module
**NCT ID:** NCT06412497

**Brief Title:** MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

**Official Title:** MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

#### Organization Study ID Info
**ID:** 2023LS101
#### Organization
**Class:** OTHER
**Full Name:** Masonic Cancer Center, University of Minnesota
### Status Module
#### Completion Date
**Date:** 2036-05-01

**Type:** ESTIMATED

#### Expanded Access Info
#### Last Update Post Date
**Date:** 2024-05-14

**Type:** ACTUAL

**Last Update Submit Date:** 2024-05-09

**Overall Status:** NOT_YET_RECRUITING

#### Primary Completion Date
**Date:** 2035-05-01

**Type:** ESTIMATED

#### Start Date
**Date:** 2024-07-01

**Type:** ESTIMATED

**Status Verified Date:** 2024-05

#### Study First Post Date
**Date:** 2024-05-14
**Type:** ACTUAL
**Study First Submit Date:** 2024-05-09
**Study First Submit QC Date:** 2024-05-09
### Sponsor Collaborators Module

#### Lead Sponsor

**Class:** OTHER

**Name:** Masonic Cancer Center, University of Minnesota

#### Responsible Party

**Type:** SPONSOR

### Oversight Module

**Is FDA Regulated Device:** False

**Is FDA Regulated Drug:** True

**Is US Export:** False

**Oversight Has DMC:** True

### Description Module

**Brief Summary:** A phase II trial of a reduced intensity conditioned (RIC) allogeneic hematopoietic cell transplant (HCT) with post-transplant cyclophosphamide (PTCy) for idiopathic severe aplastic anemia (SAA), paroxysmal nocturnal hemoglobinuria (PNH), acquired pure red cell aplasia (aPRCA), or acquired amegakaryocytic thrombocytopenia (aAT) utilizing population pharmacokinetic (popPK)-guided individual dosing of pre-transplant conditioning and differential dosing of low dose total body irradiation based on age, presence of myelodysplasia and/or clonal hematopoiesis.

### Conditions Module

**Conditions:**

- Severe Aplastic Anemia

- Acquired Amegakaryocytic Thrombocytopenia

- Acquired Pure Red Cell Aplasia

- Paroxysmal Nocturnal Hemoglobinuria

**Keywords:**

- HCT

- RIC

- SAA

- PTCy

- aAT

- aPRCA

### Design Module

#### Design Info

**Allocation:** NON_RANDOMIZED

**Intervention Model:** PARALLEL

##### Masking Info

**Masking:** NONE

**Primary Purpose:** TREATMENT

#### Enrollment Info

**Count:** 60

**Type:** ESTIMATED

**Phases:**

- PHASE2

**Study Type:** INTERVENTIONAL

### Arms Interventions Module

#### Arm Group 1

**Description:** Participants 25 years of age and younger with no clonal hematopoiesis. Active study treatment includes the conditioning regimen followed by the stem cell infusion and GvHD prophylaxis through day +180. Supportive care and follow up activities continue through two years post HCT.

**Intervention Names:**

- Drug: Rituximab

- Drug: Rabbit ATG

- Drug: Cyclophosphamide

- Drug: Fludarabine

- Radiation: Total Body Irradiation

- Biological: Cell Infusion

- Drug: Post-Transplant G-CSF

- Drug: Tacrolimus

- Drug: Mycophenolate Mofetil

**Label:** Arm A: No clonal hematopoiesis

**Type:** EXPERIMENTAL

#### Arm Group 2

**Description:** Participants 25-75 years old and/or with clonal hematopoiesis. Active study treatment includes the conditioning regimen followed by the stem cell infusion and GvHD prophylaxis through day +180. Supportive care and follow up activities continue through two years post HCT.

**Intervention Names:**

- Drug: Rituximab

- Drug: Rabbit ATG

- Drug: Cyclophosphamide

- Drug: Fludarabine

- Radiation: Total Body Irradiation

- Biological: Cell Infusion

- Drug: Post-Transplant G-CSF

- Drug: Tacrolimus

- Drug: Mycophenolate Mofetil

**Label:** Arm B: Clonal hematopoiesis

**Type:** EXPERIMENTAL

### Interventions

#### Intervention 1

**Arm Group Labels:**

- Arm A: No clonal hematopoiesis

- Arm B: Clonal hematopoiesis

**Description:** For patients with EBV IgG seropositivity or EBV PCR positivity on pre-transplant evaluations, Rituximab 375 mg/m2 is given IV once on day -14 (+/-2 day) in the outpatient setting. Pre-medicate 30 minutes prior to rituximab with methylprednisolone (1 mg/kg) IV, acetaminophen 15 mg/kg (maximum 650mg) IV or PO and diphenhydramine 1 mg/kg (maximum 50mg) IV or PO.

**Name:** Rituximab

**Type:** DRUG

#### Intervention 2

**Arm Group Labels:**

- Arm A: No clonal hematopoiesis

- Arm B: Clonal hematopoiesis

**Description:** Rabbit ATG will be administered at doses and days indicated above, infused through a 0.22 micrometer filter over 4-6 hours. Pre-medicate 30 minutes prior to ATG infusion with methylprednisolone 1 mg/kg IV, (max dose = 125 mg), acetaminophen 15 mg/kg dose (max dose = 650 mg) enterally and diphenhydramine 1 mg/kg/dose (max dose = 50 mg) enterally or IV.

**Name:** Rabbit ATG

**Other Names:**

- Thymoglobulin

**Type:** DRUG

#### Intervention 3

**Arm Group Labels:**

- Arm A: No clonal hematopoiesis

- Arm B: Clonal hematopoiesis

**Description:** Cyclophosphamide 14.5 mg/kg is be given as a 2-hour infusion on day -6. If the patient is obese (actual body weight (ABW) \>/= 125% of the ideal body weight (IBW)), cyclophosphamide should be dosed using the adjusted body weight (AdjBW): 0.5(ABW-IBW) + IBW. Uroprotection with MESNA (14.5 mg/kg/day) in IV continuous infusion will be provided per institutional guidelines. Hyperhydration is not required for 14.5 mg/kg cyclophosphamide doses.

Cyclophosphamide will be administered at 50 mg/kg using ABW over 2 hours on days +3 and +4. If the patient is obese (ABW \>/= 125% of the ideal body weight (IBW)), cyclophosphamide should be dosed using the adjusted body weight (AdjBW): 0.5(ABW-IBW) + IBW. Uroprotection with MESNA (50 mg/kg/day) in IV continuous infusion as well as hyperhydration will be provided per institutional guidelines.

**Name:** Cyclophosphamide

**Type:** DRUG

#### Intervention 4

**Arm Group Labels:**

- Arm A: No clonal hematopoiesis

- Arm B: Clonal hematopoiesis

**Description:** For all patients, fludarabine dosing will be model-based using Bayesian methodology IV every 24 hours on days -6 to -3 with a cumulative area under the curve (cAUC) of 20 mg\*hr/L.

**Name:** Fludarabine

**Type:** DRUG

#### Intervention 5

**Arm Group Labels:**

- Arm A: No clonal hematopoiesis

- Arm B: Clonal hematopoiesis

**Description:** For patients age \>/= 25 years, with myelodysplasia, or clonal hematopoiesis, total body irradiation will be 4 Gy, provided in two fractions on day -1. For all other patients, total body irradiation will be 2 Gy provided in a single fraction on day -1.

Each dose of 2 Gy will be given at a dose rate between 1 and 1.9 Gy/minute prescribed to the midplane of the patient at the level of the umbilicus.

**Name:** Total Body Irradiation

**Other Names:**

- TBI

**Type:** RADIATION

#### Intervention 6

**Arm Group Labels:**

- Arm A: No clonal hematopoiesis

- Arm B: Clonal hematopoiesis

**Description:** On day 0 the cells will be infused per cell source specific institutional guidelines.

**Name:** Cell Infusion

**Type:** BIOLOGICAL

#### Intervention 7

**Arm Group Labels:**

- Arm A: No clonal hematopoiesis

- Arm B: Clonal hematopoiesis

**Description:** Beginning on day +5, patients will receive G-CSF SQ or IV 5 micrograms/kg once daily until post-nadir ANC \> 1500/μL for 3 consecutive days or \>3000/μL for 1 day.

**Name:** Post-Transplant G-CSF

**Other Names:**

- Filgrastim

**Type:** DRUG

#### Intervention 8

**Arm Group Labels:**

- Arm A: No clonal hematopoiesis

- Arm B: Clonal hematopoiesis

**Description:** Tacrolimus will begin on day +5 at an initial dose of 0.03 mg/kg/day IV via continuous infusion. Goal trough levels will be 10-15 ug/mL until day +14 posttransplant, then decreased to a goal of 5-10 ng/mL thereafter. In the absence of GvHD, tacrolimus will discontinue at day +180 without a taper.

**Name:** Tacrolimus

**Type:** DRUG

#### Intervention 9

**Arm Group Labels:**

- Arm A: No clonal hematopoiesis

- Arm B: Clonal hematopoiesis

**Description:** Mycophenolate mofetil (MMF) therapy will begin on day +5. For pediatric service patients dosing of MMF will be 15 mg/kg/dose (max = 1000 mg) three times daily. For adult service patients dosing of MMF will be 15 mg/kg/dose (max = 1500 mg) twice daily. The same dosage is used orally or intravenously. Consider dose modification and/or pharmacokinetic measurements if renal and/or hepatic impairment (GFR\<25 mL/minute corrected). Stop MMF at Day +35 or 7 days after engraftment achieved (ANC\>500 x 106 neutrophils/L x 3 days) if later than day +35. If sufficient acute GvHD is observed to require systemic therapy, MMF should be continued for 7 days after initiation of systemic therapy. Afterward, use of MMF is at the discretion of the treating physician.

**Name:** Mycophenolate Mofetil

**Other Names:**

- MMF

**Type:** DRUG

### Outcomes Module

#### Primary Outcomes

**Description:** Incidence of grade 3-4 acute graft-versus host disease (GvHD) at 1 year post HCT.

**Measure:** Incidence of grade 3-4 acute GvHD

**Time Frame:** 1 year post HCT

**Description:** Incidence of chronic GvHD-free, failure-free survival (GFFS) 1 year post HCT

**Measure:** Incidence of chronic GvHD-free, failure-free survival (GFFS)

**Time Frame:** 1 year post HCT

**Description:** Incidence of chronic GvHD-free survival at 1 year post HCT

**Measure:** Incidence of chronic GvHD-free survival

**Time Frame:** 1 year post HCT

#### Secondary Outcomes

**Description:** Incidence of chronic GvHD-free, failure-free survival (GFFS) 2 years post HC

**Measure:** Incidence of failure-free survival (GFFS)

**Time Frame:** 2 years post HCT

**Description:** Incidence of neutrophil recovery at day 42 post HCT

**Measure:** Incidence of neutrophil recovery

**Time Frame:** Day 42 post HCT

**Description:** Incidence of platelet recovery at 6 months post HCT

**Measure:** Incidence of platelet recovery

**Time Frame:** 6 months post HCT

**Description:** Incidence of grade 3-4 acute GvHD at 100 days post HCT

**Measure:** Incidence of grade 3-4 acute GvHD

**Time Frame:** 100 days post HCT

**Description:** Incidence of any chronic GvHD at 1 year post HCT

**Measure:** Incidence of any chronic GvHD

**Time Frame:** 1 year post HCT

**Description:** Overall survival at 1 and 2 years

**Measure:** Overall survival

**Time Frame:** 1 and 2 years post HCT

**Description:** Incidence of chronic GvHD-free survival at 2 years post HCT

**Measure:** Incidence of chronic GvHD-free survival

**Time Frame:** 2 years post HCT

### Eligibility Module

**Eligibility Criteria:** Inclusion Criteria:

* Idiopathic Severe Aplastic Anemia (SAA), characterized by one of the following:

  1. Refractory cytopenia(s), with 1+ of the following:

     1. Platelets \<20,000/uL or transfusion dependent
     2. Absolute neutrophil count \<500/uL without hematopoietic growth factor support
     3. Absolute reticulocyte count \<60,000/uL AND bone marrow cellularity \<50% (with \< 30% residual hematopoietic cells)
  2. Early myelodysplastic features (bone marrow (BM) blasts \<5%), without history of MDS/AML pre-treatment.
  3. Idiopathic SAA with post-HCT graft failure (blood/marrow donor chimerism \<5%) requiring a 2nd allogeneic HCT
* Paroxysmal Nocturnal Hemoglobinuria (PNH), including AA-PNH overlap syndrome, acquired pure red cell aplasia (aPRCA), or acquired amegakaryocytic thrombocytopenia (aAT), characterized by one of the following:

  1. Refractory cytopenia(s), with 1+ of the following:

     1. Platelets \<20,000/uL or transfusion dependent
     2. Absolute neutrophil count \<500/uL without hematopoietic growth factor support
     3. Absolute reticulocyte count \<60,000/uL or red cell transfusion dependent AND Bone marrow evidence of 1 to 3-lineage aplasia OR peripheral blood PNH clone \>/= 10%
  2. Early myelodysplastic features (bone marrow (BM) blasts \<5%) without history of MDS/AML pre-treatment.
  3. Idiopathic PNH, aPRCA, or aAT with post-HCT graft failure (blood/marrow donor chimerism \<5%) requiring a 2nd allogeneic HCT
* Adequate organ function within 30 days of conditioning regimen

Exclusion Criteria:

* Pregnant, breastfeeding or intending to become pregnant during the study. Persons of childbearing potential must have a negative pregnancy test (serum or urine) within 7 days of the start of treatment
* Uncontrolled infection
* Evidence of moderate or severe portal fibrosis or cirrhosis on biopsy
* Known allergy to any of the study components
* Prior radiation therapy deemed excessive by radiation therapist for proposed low dose TBI exposure on this protocol
* Diagnosis of an inherited bone marrow failure disorder such as Fanconi anemia, Telomere biology disorder, or Schwachman-Diamond syndrome, unless reviewed by the principal investigator and deemed appropriate for this approach (e.g. GATA2 deficiency)
* Advanced myelodysplastic syndrome (MDS; BM blasts \>5%) or acute myeloid leukemia
* Psychiatric illness/social situations that, in the judgement of the enrolling Investigator, would limit compliance with study requirements
* Other illness or a medical issue that, in the judgement of the enrolling Investigator, would exclude the patient from participating in this study

**Maximum Age:** 75 Years

**Minimum Age:** 0 Years

**Sex:** ALL

**Standard Ages:**

- CHILD

- ADULT

- OLDER_ADULT

### Contacts Locations Module

#### Central Contacts

**Contact 1:**

**Email:** ebens012@umn.edu

**Name:** Christen Ebens, MD, MPH

**Phone:** 612-624-1791

**Role:** CONTACT

## Derived Section

### Condition Browse Module - Ancestors

- ID: D000006402

- Term: Hematologic Diseases

- ID: D000001791

- Term: Blood Platelet Disorders

- ID: D000095542

- Term: Cytopenia

- ID: D000001855

- Term: Bone Marrow Diseases

- ID: D000011507

- Term: Proteinuria

- ID: D000014555

- Term: Urination Disorders

- ID: D000014570

- Term: Urologic Diseases

- ID: D000052776

- Term: Female Urogenital Diseases

- ID: D000005261

- Term: Female Urogenital Diseases and Pregnancy Complications

- ID: D000091642

- Term: Urogenital Diseases

- ID: D000052801

- Term: Male Urogenital Diseases

- ID: D000020924

- Term: Urological Manifestations

- ID: D000000743

- Term: Anemia, Hemolytic

- ID: D000009190

- Term: Myelodysplastic Syndromes

### Condition Browse Module - Browse Branches

- Abbrev: BC15

- Name: Blood and Lymph Conditions

- Abbrev: All

- Name: All Conditions

- Abbrev: BXS

- Name: Urinary Tract, Sexual Organs, and Pregnancy Conditions

- Abbrev: BC23

- Name: Symptoms and General Pathology

- Abbrev: BC04

- Name: Neoplasms

- Abbrev: Rare

- Name: Rare Diseases

### Condition Browse Module - Browse Leaves

- ID: M4070

- Name: Anemia

- Relevance: HIGH

- As Found: Anemia

- ID: M16680

- Name: Thrombocytopenia

- Relevance: HIGH

- As Found: Thrombocytopenia

- ID: M4071

- Name: Anemia, Aplastic

- Relevance: HIGH

- As Found: Aplastic Anemia

- ID: M9542

- Name: Hemoglobinuria

- Relevance: HIGH

- As Found: Hemoglobinuria

- ID: M13118

- Name: Pancytopenia

- Relevance: HIGH

- As Found: Bone Marrow Failure

- ID: M14852

- Name: Red-Cell Aplasia, Pure

- Relevance: HIGH

- As Found: Pure Red Cell Aplasia

- ID: M9543

- Name: Hemoglobinuria, Paroxysmal

- Relevance: HIGH

- As Found: Paroxysmal Nocturnal Hemoglobinuria

- ID: M2241

- Name: Bone Marrow Failure Disorders

- Relevance: HIGH

- As Found: Bone Marrow Failure

- ID: M9490

- Name: Hematologic Diseases

- Relevance: LOW

- As Found: Unknown

- ID: M5072

- Name: Blood Platelet Disorders

- Relevance: LOW

- As Found: Unknown

- ID: M3170

- Name: Cytopenia

- Relevance: LOW

- As Found: Unknown

- ID: M5134

- Name: Bone Marrow Diseases

- Relevance: LOW

- As Found: Unknown

- ID: M14368

- Name: Proteinuria

- Relevance: LOW

- As Found: Unknown

- ID: M17305

- Name: Urination Disorders

- Relevance: LOW

- As Found: Unknown

- ID: M17319

- Name: Urologic Diseases

- Relevance: LOW

- As Found: Unknown

- ID: M2875

- Name: Urogenital Diseases

- Relevance: LOW

- As Found: Unknown

- ID: M27093

- Name: Female Urogenital Diseases

- Relevance: LOW

- As Found: Unknown

- ID: M14127

- Name: Pregnancy Complications

- Relevance: LOW

- As Found: Unknown

- ID: M8399

- Name: Female Urogenital Diseases and Pregnancy Complications

- Relevance: LOW

- As Found: Unknown

- ID: M27095

- Name: Male Urogenital Diseases

- Relevance: LOW

- As Found: Unknown

- ID: M22659

- Name: Urological Manifestations

- Relevance: LOW

- As Found: Unknown

- ID: M9547

- Name: Hemolysis

- Relevance: LOW

- As Found: Unknown

- ID: M4073

- Name: Anemia, Hemolytic

- Relevance: LOW

- As Found: Unknown

- ID: M16355

- Name: Syndrome

- Relevance: LOW

- As Found: Unknown

- ID: M14164

- Name: Preleukemia

- Relevance: LOW

- As Found: Unknown

- ID: M12145

- Name: Myelodysplastic Syndromes

- Relevance: LOW

- As Found: Unknown

- ID: T460

- Name: Aplastic Anemia

- Relevance: HIGH

- As Found: Aplastic Anemia

- ID: T4436

- Name: Paroxysmal Nocturnal Hemoglobinuria

- Relevance: HIGH

- As Found: Paroxysmal Nocturnal Hemoglobinuria

- ID: T4833

- Name: Pure Red Cell Aplasia

- Relevance: HIGH

- As Found: Pure Red Cell Aplasia

- ID: T114

- Name: Acquired Pure Red Cell Aplasia

- Relevance: HIGH

- As Found: Acquired Pure Red Cell Aplasia

- ID: T109

- Name: Acquired Amegakaryocytic Thrombocytopenia

- Relevance: HIGH

- As Found: Acquired Amegakaryocytic Thrombocytopenia

- ID: T3993

- Name: Myelodysplastic Syndromes

- Relevance: LOW

- As Found: Unknown

### Condition Browse Module - Meshes

- ID: D000006456

- Term: Hemoglobinuria

- ID: D000000740

- Term: Anemia

- ID: D000013921

- Term: Thrombocytopenia

- ID: D000000741

- Term: Anemia, Aplastic

- ID: D000006457

- Term: Hemoglobinuria, Paroxysmal

- ID: D000080983

- Term: Bone Marrow Failure Disorders

- ID: D000010198

- Term: Pancytopenia

- ID: D000012010

- Term: Red-Cell Aplasia, Pure

### Intervention Browse Module - Ancestors

- ID: D000007166

- Term: Immunosuppressive Agents

- ID: D000007155

- Term: Immunologic Factors

- ID: D000045505

- Term: Physiological Effects of Drugs

- ID: D000018501

- Term: Antirheumatic Agents

- ID: D000018906

- Term: Antineoplastic Agents, Alkylating

- ID: D000000477

- Term: Alkylating Agents

- ID: D000045504

- Term: Molecular Mechanisms of Pharmacological Action

- ID: D000000970

- Term: Antineoplastic Agents

- ID: D000019653

- Term: Myeloablative Agonists

- ID: D000074322

- Term: Antineoplastic Agents, Immunological

- ID: D000065095

- Term: Calcineurin Inhibitors

- ID: D000004791

- Term: Enzyme Inhibitors

- ID: D000000903

- Term: Antibiotics, Antineoplastic

- ID: D000000904

- Term: Antibiotics, Antitubercular

- ID: D000000995

- Term: Antitubercular Agents

- ID: D000000900

- Term: Anti-Bacterial Agents

- ID: D000000890

- Term: Anti-Infective Agents

### Intervention Browse Module - Browse Branches

- Abbrev: ANeo

- Name: Antineoplastic Agents

- Abbrev: ARhu

- Name: Antirheumatic Agents

- Abbrev: All

- Name: All Drugs and Chemicals

- Abbrev: Antipy

- Name: Antipyretics

- Abbrev: Analg

- Name: Analgesics

- Abbrev: Infl

- Name: Anti-Inflammatory Agents

- Abbrev: Infe

- Name: Anti-Infective Agents

- Abbrev: AnEm

- Name: Antiemetics

- Abbrev: NeuroAg

- Name: Neuroprotective Agents

- Abbrev: Gast

- Name: Gastrointestinal Agents

- Abbrev: AAll

- Name: Anti-Allergic Agents

- Abbrev: CNSDep

- Name: Central Nervous System Depressants

- Abbrev: Derm

- Name: Dermatologic Agents

### Intervention Browse Module - Browse Leaves

- ID: M6727

- Name: Cyclophosphamide

- Relevance: HIGH

- As Found: Cycle

- ID: M283230

- Name: Fludarabine

- Relevance: HIGH

- As Found: Combined

- ID: M225513

- Name: Fludarabine phosphate

- Relevance: LOW

- As Found: Unknown

- ID: M2340

- Name: Acetaminophen

- Relevance: LOW

- As Found: Unknown

- ID: M373

- Name: Rituximab

- Relevance: HIGH

- As Found: Healthy

- ID: M14120

- Name: Prednisolone

- Relevance: LOW

- As Found: Unknown

- ID: M1945

- Name: Lenograstim

- Relevance: LOW

- As Found: Unknown

- ID: M12128

- Name: Mycophenolic Acid

- Relevance: HIGH

- As Found: Lifestyle

- ID: M18950

- Name: Tacrolimus

- Relevance: HIGH

- As Found: 3 weeks

- ID: M255823

- Name: Thymoglobulin

- Relevance: HIGH

- As Found: Doctor

- ID: M11749

- Name: Methylprednisolone

- Relevance: LOW

- As Found: Unknown

- ID: M1833

- Name: Methylprednisolone Acetate

- Relevance: LOW

- As Found: Unknown

- ID: M11750

- Name: Methylprednisolone Hemisuccinate

- Relevance: LOW

- As Found: Unknown

- ID: M229449

- Name: Prednisolone acetate

- Relevance: LOW

- As Found: Unknown

- ID: M211887

- Name: Prednisolone hemisuccinate

- Relevance: LOW

- As Found: Unknown

- ID: M248881

- Name: Prednisolone phosphate

- Relevance: LOW

- As Found: Unknown

- ID: M7338

- Name: Diphenhydramine

- Relevance: LOW

- As Found: Unknown

- ID: M14268

- Name: Promethazine

- Relevance: LOW

- As Found: Unknown

- ID: M17811

- Name: Mesna

- Relevance: LOW

- As Found: Unknown

- ID: M10212

- Name: Immunosuppressive Agents

- Relevance: LOW

- As Found: Unknown

- ID: M10201

- Name: Immunologic Factors

- Relevance: LOW

- As Found: Unknown

- ID: M20604

- Name: Antirheumatic Agents

- Relevance: LOW

- As Found: Unknown

- ID: M20942

- Name: Antineoplastic Agents, Alkylating

- Relevance: LOW

- As Found: Unknown

- ID: M3820

- Name: Alkylating Agents

- Relevance: LOW

- As Found: Unknown

- ID: M1346

- Name: Antineoplastic Agents, Immunological

- Relevance: LOW

- As Found: Unknown

- ID: M30452

- Name: Calcineurin Inhibitors

- Relevance: LOW

- As Found: Unknown

- ID: M7951

- Name: Enzyme Inhibitors

- Relevance: LOW

- As Found: Unknown

- ID: M4222

- Name: Anti-Bacterial Agents

- Relevance: LOW

- As Found: Unknown

- ID: M4224

- Name: Antibiotics, Antitubercular

- Relevance: LOW

- As Found: Unknown

- ID: M4311

- Name: Antitubercular Agents

- Relevance: LOW

- As Found: Unknown

- ID: M4214

- Name: Anti-Infective Agents

- Relevance: LOW

- As Found: Unknown

### Intervention Browse Module - Meshes

- ID: D000009173

- Term: Mycophenolic Acid

- ID: D000003520

- Term: Cyclophosphamide

- ID: D000069283

- Term: Rituximab

- ID: C000024352

- Term: Fludarabine

- ID: D000016559

- Term: Tacrolimus

- ID: C000512542

- Term: Thymoglobulin

### Misc Info Module

- Version Holder: 2024-05-31
